nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease
|
Eastham, James A |
|
2003 |
62 |
S |
p. 55-62 8 p. |
artikel |
2 |
Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer
|
Hellerstedt, Beth |
|
2003 |
62 |
S |
p. 79-86 8 p. |
artikel |
3 |
Introduction
|
Pienta, Kenneth J. |
|
2003 |
62 |
S |
p. 1- 1 p. |
artikel |
4 |
Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer
|
Kumar-Sinha, Chandan |
|
2003 |
62 |
S |
p. 19-35 17 p. |
artikel |
5 |
Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer
|
Dawson, Nancy A |
|
2003 |
62 |
S |
p. 102-118 17 p. |
artikel |
6 |
Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient
|
Gulley, James |
|
2003 |
62 |
S |
p. 147-154 8 p. |
artikel |
7 |
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), intergroup/clinical trials support unit study
|
Walczak, Janet R |
|
2003 |
62 |
S |
p. 141-146 6 p. |
artikel |
8 |
Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer
|
Loberg, Robert D |
|
2003 |
62 |
S |
p. 128-133 6 p. |
artikel |
9 |
Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer
|
Cannon Jr, Glenn M |
|
2003 |
62 |
S |
p. 2-8 7 p. |
artikel |
10 |
Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy
|
Pienta, Kenneth J |
|
2003 |
62 |
S |
p. 95-101 7 p. |
artikel |
11 |
Role of secondary hormonal therapy in the management of recurrent prostate cancer
|
Ryan, Charles J |
|
2003 |
62 |
S |
p. 87-94 8 p. |
artikel |
12 |
Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer
|
Chen, Bert T |
|
2003 |
62 |
S |
p. 69-78 10 p. |
artikel |
13 |
Salvage radiotherapy in the treatment of prostate cancer
|
Tsien, Christina |
|
2003 |
62 |
S |
p. 63-68 6 p. |
artikel |
14 |
The patient with hormone-refractory prostate cancer: determining who, when, and how to treat
|
Kent, Elizabeth C |
|
2003 |
62 |
S |
p. 134-140 7 p. |
artikel |
15 |
Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer
|
Pisansky, Thomas M |
|
2003 |
62 |
S |
p. 36-45 10 p. |
artikel |
16 |
Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer
|
Gomella, Leonard G |
|
2003 |
62 |
S |
p. 46-54 9 p. |
artikel |
17 |
Use of nomograms for predicting survival in patients with castrate prostate cancer
|
Galsky, Matt |
|
2003 |
62 |
S |
p. 119-127 9 p. |
artikel |
18 |
Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer
|
Diblasio, Christopher J |
|
2003 |
62 |
S |
p. 9-18 10 p. |
artikel |